Antibiotics used for plant disease control — such as streptomycin sulphate with tetracycline hydrochloride, kasugamycin, validamycin and aureofungin — are listed in the Schedule to the Insecticides Act, 1968 and must be registered with CIB&RC. The dossier must address fermentation source, potency and bio-assay, efficacy against the named bacterial or fungal disease, and residues.
A category under permanent review
Agricultural antibiotics occupy sensitive ground. They are genuinely useful against bacterial diseases that no conventional fungicide controls — bacterial blight, bacterial leaf spot, canker — but their use intersects with antimicrobial resistance concerns that reach well beyond agriculture. The consequence for an applicant is that these files are examined more conservatively than others, restrictions on crops and doses are tighter, and label claims are granted narrowly.
We think it is only honest to say so at the outset: antibiotic registrations are achievable, but they reward a conservative, well-evidenced claim and punish an ambitious one.
Antibiotics registered under the Act
The most common filings involve streptomycin sulphate in combination with tetracycline hydrochloride (typically in a 9:1 ratio), kasugamycin as a solution and in combination with copper oxychloride, validamycin, and aureofungin for fungal disease control. Each has its own analytical and potency conventions, which is where a good deal of the technical work sits.
What makes an antibiotic dossier technically distinctive
- Source and process. These are fermentation products. The producing organism, fermentation process, downstream purification and the resulting impurity profile all have to be documented, and consistency across batches matters more than for a synthesised molecule.
- Potency, not just percentage. Content is often expressed in potency units and determined by microbiological bio-assay. The assay method, its validation and its reference standard have to be submitted and defended.
- Stability. Many antibiotic actives are sensitive to heat, light and pH. Shelf-life data has to reflect real Indian storage conditions, and packaging selection is part of the technical case.
- Efficacy against a named pathogen. Trials must target the specific bacterial or fungal disease claimed, in the crop claimed, across seasons and locations with adequate disease pressure.
- Residues and waiting period. Residue data is scrutinised closely given the human-health context, and the resulting pre-harvest interval is often longer than applicants expect.
- Stewardship on the label. Restrictions on number of sprays, crops, and use in combination are commonly imposed and must be reflected in the leaflet.
How we approach these files
We start with a realistic assessment of what claim is obtainable, based on what is already registered and what the current regulatory posture is toward the active. We then design the data package around that claim rather than around the maximum commercially desirable claim. In practice this means fewer crops on the first certificate, a defensible waiting period, and a file that clears rather than one that sits on the agenda while the Committee asks for more.